A History of Excellence

Cytori is committed to developing and commercializing  specialty therapeutics.

Since 2002, Cytori has enabled researchers and clinicians to study and administer cell therapies using our novel Celution® System platform which harnesses the potential of stem and regenerative cells from adipose tissue.

In 2017, Cytori strengthened its specialty therapeutics position by acquiring a nanomedicine platform technology that combines widely-known and prescribed chemotherapy agents, doxorubicin and docetaxel, both with liposomal encapsulation technology.

This marriage of technologies has the potential to improve patient care for both life-debilitating and life-threatening conditions and diseases. .

Mission and Values

Cytori Therapeutics, Inc. is dedicated to enhancing lives through the development of novel therapeutics. To realize this mission, Cytori defines, develops, and delivers specialty therapeutics that address poorly met market and medical needs. Through constantly balancing a blend of creativity, rigor, focused energy, and agility, we strive to deliver meaningful results that create exceptional value for patients, customers, partners, employees, shareholders, and society.

  • We do what is right, deliver what we promise and own the outcome.
  • We place our patients and customers at the heart of everything we do.
  • We thoughtfully balance competing priorities to achieve important results.
  • We are an agile company that embraces big challenges.
  • We value spirited communication and care about one another.

Management Team

Board of Directors